Drug Profile
Research programme: Alzheimer's disease therapeutics - Serometrix
Alternative Names: SX-AZD1Latest Information Update: 28 Aug 2020
Price :
$50
*
At a glance
- Originator Serometrix
- Class Antidementias
- Mechanism of Action Apolipoprotein E modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 28 Aug 2020 No recent reports of development identified for research development in Alzheimer's-disease in USA
- 12 Jul 2016 Early research in Alzheimer's disease in USA (unspecified route)